Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
21 Février 2018 - 11:26PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced the granting of inducement awards to 47 new
employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the
awards were approved by Insmed's Compensation Committee and made as
a material inducement to each employee's entry into employment with
the Company.
In connection with the February 20, 2018 commencement of their
employment, the employees received options to purchase an aggregate
133,010 shares of Insmed common stock at an exercise price of
$24.22 per share, the closing trading price on the Nasdaq Global
Select Market on the date of grant.
The options have a ten-year term and a four-year vesting
schedule, with 25% of the shares subject to the option vesting on
the first anniversary of the relevant grant date and 12.5% of the
shares subject to the option vesting every six months thereafter
through the fourth anniversary of the relevant grant date, subject
to the relevant employee's continued service with Insmed on the
applicable vesting date.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
Company’s lead product candidate is ALIS for adult patients with
treatment refractory NTM lung disease caused by MAC, which is a
rare and often chronic infection that is capable of causing
irreversible lung damage and can be fatal. Insmed's
earlier-stage clinical pipeline includes INS1007, a novel oral
reversible inhibitor of dipeptidyl peptidase 1 with therapeutic
potential in non-cystic fibrosis bronchiectasis, and INS1009, an
inhaled nanoparticle formulation of a treprostinil prodrug that may
offer a differentiated product profile for rare pulmonary
disorders, including pulmonary arterial hypertension. For
more information, visit www.insmed.com.
Investor Contact:Blaine Davis Vice President, Head of Investor
Relations Insmed Incorporated (908) 947-2841
blaine.davis@insmed.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024